NoL and BIS Monitoring on Patients Recovery and Safety After Surgery
Launched by MAISONNEUVE-ROSEMONT HOSPITAL · Jan 18, 2018
Trial Information
Current as of June 10, 2025
Unknown status
Keywords
ClinConnect Summary
Hypothesis is that the intraoperative use of the combination of 1) the NoL index (given by the PMD200TM monitor, Medasense LTD inc, Ramat, Israel) to monitor pain levels and to guide opioids' administration during surgery, and 2) the BIS index (Medtronic, St-Laurent, QC, Canada) to monitor the depth of hypnosis during anesthesia and to guide the administration of anesthetic halogenous gases, will improve the quality of recovery as well as the safety after anesthesia in ERAS (Early Rehabilitation After Surgery) patients undergoing colonic surgery under general anesthesia + epidural analgesia...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • ASA status I, II or III
- • Patients aged 18 years
- • Colo-rectal surgery
- • Duration and type of surgery requiring an epidural analgesia via an epidural catheter placed prior the general anesthesia induction and an arterial line placed after induction of general anesthesia (classical management of ERAS program patients in our center)
- Exclusion Criteria:
- • chronic arhythmic condition
- • chronic pain
- * Adverse events prompting termination of protocol:
- • Unexpected difficult airway requesting excessive, possibly painful airway manipulations.
- • Unexpected surgical complications requiring strong haemodynamic support (transfusions, volume challenges, vasopressors, inotropic drugs)
About Maisonneuve Rosemont Hospital
Maisonneuve-Rosemont Hospital, a leading healthcare institution in Montreal, Canada, is dedicated to advancing medical research and improving patient care through innovative clinical trials. With a strong emphasis on multidisciplinary collaboration, the hospital leverages its state-of-the-art facilities and expertise in various specialties to conduct rigorous clinical studies. Committed to ethical standards and patient safety, Maisonneuve-Rosemont Hospital fosters an environment that encourages scientific inquiry and the translation of research findings into clinical practice, ultimately aiming to enhance treatment options and health outcomes for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Montreal, Quebec, Canada
Patients applied
Trial Officials
Philippe Richebé, Md, PhD
Principal Investigator
Full Professor
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials